Spatial Biology Market Size, Share & Forecast 2026-2032
Spatial biology market at $1.40B in 2026, reaching $3.32B by 2032 at 15.5%. Published estimates span 16.9x; two vendors' disclosed revenue tests them.
$1.4B
$3.3B
15.5%
Global
Executive Summary
Spatial biology is the rare market in this corpus where the grounding arithmetic says the published figures are too small. Estimates span 16.9x, from Arizton's $383.93 million for 2024 to a $6.5 billion figure for 2025 attributed to Roots Analysis — and the two extremes claim the same scope, spatial transcriptomics and genomics, which means they cannot both be measurements. Stranger still, the publisher carrying the $6.5 billion narrow-scope number publishes $1.20 billion for 2025 on the wider scope that contains it, a subset larger than its superset by 5.4x. We set that series aside and build on Roots Analysis' spatial-biology series, which is the only one whose published endpoints reconcile with its own published rate to better than 1%: $1.40 billion in 2026 rising to $3.32 billion by 2032 at 15.5%. The test that decides the scope question uses the only two companies that have disclosed spatial revenue for a common year. 10x Genomics' FY2024 spatial revenue, back-solved from the growth rates in its January 2026 filing, was about $178.8 million; Akoya Biosciences reported $81.7 million. Together $260.5 million — 67.9% of Arizton's whole-market total and 47.0% of MarketsandMarkets'. That leaves as little as $123 million for Bruker's NanoString platforms, Standard BioTools' Hyperion, Vizgen, Curio and the rest of the field, which is not credible when Bruker describes its spatial business as growing at low double digits. The narrow-scope totals measure a part of the market and are being read as the whole of it.
Key Highlights
Headline
$1.40 billion in 2026 to $3.32 billion in 2032 at 15.5%, built on Roots Analysis' own published 2026 base and rate
Published estimates span 16.9x, and the two extremes claim the same narrow scope — one publisher's subset figure exceeds its own superset figure by 5.4x
Two disclosing vendors booked about $260.5 million of spatial revenue in FY2024, which is 67.9% of one published whole-market total and 47.0% of another
That leaves as little as $123 million for Bruker's NanoString line, Standard BioTools' Hyperion, Vizgen, Curio and the whole remaining field — so the narrow totals are too low, not too high
Meticulous Research's own $1.48 billion base and 19.3% rate give $8.64 billion for 2036, 18% below the $10.2 billion it publishes
Spatial was 10x Genomics' only growing consumables line in FY2025, up 19% to $144.0 million, while spatial instruments fell 41%
Consolidation has reduced disclosure: NanoString into Bruker, Akoya into Quanterix, with no spatial split reported by either parent
Market Overview
Market Context
Spatial biology occupies the gap between two measurement traditions. Pathology has always had tissue context and no molecular depth; genomics has molecular depth and, since dissociation became standard, no tissue context. Spatial platforms restore both at once, which is why the method spread through immuno-oncology and neuroscience faster than any commercial forecast anticipated — 8,121 PubMed records for 'spatial transcriptomics' by October 2026. Commercially, however, the sector has been absorbed rather than scaled: NanoString went into Bruker in the second quarter of 2024, Akoya into Quanterix from January 2025, and SomaLogic from Standard BioTools into Illumina in January 2026. The consequence for anyone trying to size the market is that it is less measurable now than it was in 2023. Of the major platforms, only 10x Genomics still reports spatial as a separate revenue line. This report leans heavily on that one disclosure, and on Akoya's final standalone year, precisely because they are the last clean data points before the category disappeared inside larger segment reporting.
Spatial biology measures RNA, protein or DNA while keeping the tissue coordinates of each measurement, which makes it the complement to single-cell methods rather than a competitor to them. Published sizings span 16.9x, from Arizton's $383.93 million for 2024 to a $6.5 billion figure for 2025 attributed to Roots Analysis — and both claim the same narrow scope, spatial transcriptomics and genomics. The more useful finding is that the narrow-scope totals are too low rather than too high: two disclosing vendors, 10x Genomics and Akoya Biosciences, together booked about $260.5 million of spatial revenue in FY2024, which is 67.9% of one published whole-market total and 47.0% of another, before Bruker's NanoString line or Standard BioTools' Hyperion are counted at all. We therefore publish the wider spatial-biology scope.
Market Stage
Growth
Adoption Level
Established in translational research, pre-clinical in diagnostics
Key Trends
Market Forecast & Data
Base Year (2026)
$1.4B
Forecast (2032)
$3.3B
CAGR (2026-2032)
15.5%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $1.40B |
| 2027 | $1.62B |
| 2028 | $1.87B |
| 2029 | $2.16B |
| 2030 | $2.49B |
| 2031 | $2.88B |
| 2032 | $3.32B |
We publish 15.5%, the lower of the two wide-scope published rates, from the only series whose arithmetic closes on itself. Roots Analysis' $1.40 billion for 2026 compounded at its stated 15.5% gives $5.12 billion for 2035 against its published $5.14 billion — a 0.4% gap that tells you the series was built rather than asserted. The comparison matters: Meticulous Research's $1.48 billion for 2026 at its stated 19.3% gives $8.64 billion for 2036, not the $10.2 billion it publishes, so its headline endpoint requires 21.3% rather than the rate on its own page. On the substance, 15.5% is a claim that spatial consumables pull-through keeps compounding while instrument placements recover. The first half of that is observable — 10x's spatial consumables grew 19% in FY2025 — but the second half is not: spatial instrument revenue fell 41% in the same year, and a consumables base cannot compound indefinitely on instruments that stopped being placed. Readers should treat the near-term path as consumables-led and flatter than the curve, with the rate dependent on academic and biopharma capital budgets turning. The one element genuinely unpriced in every published series is spatial proteomics and outsourced services, which the narrow-versus-wide scope gap implies is already the larger half of the market and which no publisher sizes separately.
Market Dynamics
- Tissue context answers questions single-cell dissociation destroys — immune-cell positioning relative to tumour margins is the canonical example, and it is the main reason immuno-oncology groups buy spatial platforms
- FFPE compatibility: unlike most single-cell chemistries, leading spatial assays run on archival formalin-fixed material, which unlocks existing pathology biobanks as sample supply
- An installed base that generates recurring consumables revenue: 10x's spatial consumables grew 19% in FY2025 even as its spatial instrument sales fell 41%, and Akoya disclosed 1,330 installed instruments at the end of 2024
- Biopharma translational research budgets, which fund spatial as a biomarker-discovery tool attached to specific clinical programmes rather than as general capital equipment
- Instrument vendors with distribution: Bruker and Quanterix both acquired spatial platforms into existing commercial organisations, which widens reach without widening the platform count
Market Segmentation
By Type
- Instruments and platforms
- Consumables and reagents
- Software and analytics
- Outsourced services
By End User
- Pharmaceutical and biotechnology companies
- Academic and research institutions
- Contract research organisations
- Hospitals and other clinical facilities
By Application
- Spatial transcriptomics
- Spatial proteomics
- Spatial genomics
- Spatial metabolomics
- Spatial multi-omics
Competitive Landscape
10x Genomics, Inc.
Pleasanton, California, United States
Visium and Xenium platforms, spanning sequencing-based and imaging-based spatial transcriptomics. FY2025 (preliminary, unaudited, 11 January 2026): spatial consumables $144.0 million, up 19%; spatial instruments $34.1 million, down 41%. Spatial was the only growing consumables line in the company.
Bruker Corporation
Billerica, Massachusetts, United States
FY2025 revenue $3.44 billion, up 2% reported and down 4% organic. BSI NANO segment revenue $1.08 billion, down 2%, with the decline attributed to weak academic, government and industrial demand and partly offset by NanoString. Management described the spatial biology business as growing at low double digits in 2025, with double-digit organic order growth in the fourth quarter.
Quanterix Corporation
Billerica, Massachusetts, United States
FY2025 total revenue $138.9 million, up about 1% from $137.4 million. The Form 10-K reports Akoya adding $21.9 million of product revenue from the close date — a partial period, not annualisable — while legacy product revenue fell 11%, or $8.7 million. Akoya's last full standalone year, FY2024, was $81.7 million on an installed base of 1,330 instruments.
Standard BioTools Inc.
South San Francisco, California, United States
FY2025 continuing-operations revenue $85.3 million, reported 24 February 2026, spanning microfluidics and mass cytometry. Holds roughly $550 million in cash and investments after divesting SomaLogic to Illumina on 30 January 2026, with a stated inorganic growth intent.
Vizgen, Inc.
Cambridge, Massachusetts, United States
MERFISH-based spatial transcriptomics platforms. Named because the grounding arithmetic shows the published narrow-scope totals leave very little revenue for the field outside 10x and Akoya, and this is one of the companies that field consists of.
Curio Bioscience, Inc.
Palo Alto, California, United States
Bead-array whole-transcriptome spatial kits that run without a dedicated instrument, competing on cost per tissue section rather than on hardware capability.
Recent Developments
Reported preliminary unaudited FY2025 results on 11 January 2026 showing spatial consumables revenue of $144.0 million, up 19% year-over-year, against spatial instrument revenue of $34.1 million, down 41% — making spatial the only growing consumables line in the company.
Reported FY2025 revenue of $3.44 billion on 12 February 2026, with the BSI NANO segment at $1.08 billion, down 2%; management described the spatial biology business built on the NanoString acquisition as growing at low double digits for the year with double-digit organic order growth in the fourth quarter.
Announced a definitive all-stock agreement to acquire Akoya Biosciences on 10 January 2025, bringing Akoya's spatial proteomics platforms and 1,330-instrument installed base into Quanterix; the FY2025 Form 10-K reports $21.9 million of Akoya product revenue from the close date.
Reported full-year 2024 revenue of $81.7 million, down 15.5% from $96.6 million, with the decline attributed primarily to lower instrument sales, and an installed base of 1,330 instruments at 31 December 2024 — its last full year as a standalone reporting company.
Regulatory Landscape
Research Methodology
Secondary research
- 10x Genomics, Inc., Form 8-K Exhibit 99.1, preliminary unaudited Q4 and FY2025 revenue results, 11 January 2026 (SEC EDGAR, CIK 1770787)
- Akoya Biosciences, Inc., fourth-quarter and full-year 2024 financial results — FY2024 revenue $81.7 million, installed base 1,330
- Quanterix Corporation, Form 10-K for FY2025 (SEC EDGAR, CIK 1503274) — total revenue $138.9 million, Akoya contribution $21.9 million of product revenue
- Roots Analysis, Spatial Biology Market, last updated September 2026 — $1.20B (2025), $1.40B (2026), $5.14B (2035), 15.5%
- Meticulous Research, Spatial Biology Market (report 6714), June 2026 — $1.48B (2026), $10.2B (2036), 19.3%
- MarketsandMarkets, spatial genomics and transcriptomics market — $554.5M (2024) to $995.7M (2029), 12.4%
- Arizton, Spatial Transcriptomics and Genomics Market — $383.93M (2024) to $1.00B (2030), 17.4%
- Bruker Corporation, fourth-quarter and full-year 2025 financial results, 12 February 2026 — FY2025 revenue $3.44 billion, BSI NANO $1.08 billion
- Standard BioTools Inc., Form 8-K Exhibit 99.1, Q4 and FY2025 financial results, 24 February 2026 — continuing-operations revenue $85.3 million
- PubMed (NCBI E-utilities esearch, db=pubmed), term '"spatial transcriptomics"', retrieved 16 October 2026: 8,121 records
Validation: The 2026 base of $1.40 billion is Roots Analysis' own published figure, not a derivation; the 2032 endpoint of $3.32 billion applies that house's own published 15.5% rate over six years and is labelled as interpolation. Roots was selected because it is the only series in the set whose published endpoints reconcile with its own published rate: $1.40B x 1.155^9 gives $5.12B against its published $5.14B, a 0.4% difference, whereas Meticulous Research's published $1.48B base and 19.3% rate give $8.64B for 2036 rather than the $10.2B it publishes — an 18% internal gap. The grounding calculation sums the only two disclosed spatial revenue figures available for a common year: 10x Genomics' FY2024 spatial revenue of about $178.8 million, back-solved by us from the growth rates disclosed in its 11 January 2026 Form 8-K ($144.0M divided by 1.19, and $34.1M divided by 0.59), plus Akoya Biosciences' reported FY2024 revenue of $81.7 million, giving $260.5 million. That is 67.9% of Arizton's published $383.93 million 2024 market and 47.0% of MarketsandMarkets' $554.5 million, before Bruker's NanoString line or Standard BioTools' Hyperion are counted at all, which rules both narrow-scope totals out as measures of spatial biology and rules the wider $1.2-1.5 billion range in. This is a plausibility test, not a market estimate: it does not establish the correct figure, one of its two inputs is our own back-solve rather than a reported number, and the undisclosed NanoString and Hyperion revenues mean the true two-vendor-plus total is higher than $260.5 million by an unknown amount. Regional and country arrays are empty because no named source publishes a percentage for this scope; vendor shares are omitted because none is disclosed.
Strategic Takeaways
Ask whether a published spatial figure covers proteomics and services or only transcriptomics and genomics. The difference is roughly 2-3x, and it is the whole of the apparent disagreement among the credible publishers.
Treat the sub-$600 million narrow-scope totals as a part, not the whole. Two companies alone disclosed $260.5 million for FY2024, which leaves no room for Bruker's NanoString line at the growth Bruker reports.
Check a forecast against its own arithmetic before using it. One series in this market publishes an endpoint 18% away from what its own base and rate produce.
NanoString and Akoya no longer report separately.
Separate the consumables story from the instrument story. Spatial consumables grew 19% in FY2025 while spatial instruments fell 41%, and only the second of those sets the ceiling on future growth.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Life SciencesSingle-Cell Sequencing Market$2.2B · 12.2% CAGR
- Life SciencesAntimicrobial Resistance Diagnostics Market$5.3B · 6.26% CAGR
- Life SciencesPharmacogenomics Market$6.8B · 6.6% CAGR
- Life SciencesLiquid Biopsy Market$8.0B · 13.91% CAGR
- Life SciencesVeterinary Diagnostics Market$9.5B · 9.57% CAGR
- Life SciencesProteomics Market$35.0B · 13% CAGR